- Home
- LRFC vs ACET Comparison
LRFC vs ACET Comparison
Compare LRFC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRFC
- ACET
- Stock Information
- Founded
- LRFC 2013
- ACET 1947
- Country
- LRFC United States
- ACET United States
- Employees
- LRFC N/A
- ACET N/A
- Industry
- LRFC Finance: Consumer Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- LRFC Finance
- ACET Health Care
- Exchange
- LRFC Nasdaq
- ACET Nasdaq
- Market Cap
- LRFC 49.8M
- ACET 44.4M
- IPO Year
- LRFC 2013
- ACET N/A
- Fundamental
- Price
- LRFC $18.30
- ACET $0.59
- Analyst Decision
- LRFC
- ACET Buy
- Analyst Count
- LRFC 0
- ACET 6
- Target Price
- LRFC N/A
- ACET $6.00
- AVG Volume (30 Days)
- LRFC 9.4K
- ACET 530.9K
- Earning Date
- LRFC 05-08-2025
- ACET 05-13-2025
- Dividend Yield
- LRFC 7.68%
- ACET N/A
- EPS Growth
- LRFC N/A
- ACET N/A
- EPS
- LRFC N/A
- ACET N/A
- Revenue
- LRFC $20,916,000.00
- ACET N/A
- Revenue This Year
- LRFC N/A
- ACET N/A
- Revenue Next Year
- LRFC N/A
- ACET N/A
- P/E Ratio
- LRFC N/A
- ACET N/A
- Revenue Growth
- LRFC 3.66
- ACET N/A
- 52 Week Low
- LRFC $17.30
- ACET $0.45
- 52 Week High
- LRFC $26.00
- ACET $2.25
- Technical
- Relative Strength Index (RSI)
- LRFC 34.59
- ACET 41.57
- Support Level
- LRFC $17.94
- ACET $0.51
- Resistance Level
- LRFC $18.78
- ACET $0.60
- Average True Range (ATR)
- LRFC 0.89
- ACET 0.06
- MACD
- LRFC 0.07
- ACET 0.00
- Stochastic Oscillator
- LRFC 38.81
- ACET 49.71
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.